The clinical benefits of tenofovir for simian immunodeficiency virus-infected macaques are larger than predicted by its effects on standard viral and immunologic parameters

Koen K.A. Van Rompay, Raman P. Singh, Laurie L. Brignolo, Jonathan R. Lawson, Kimberli A. Schmidt, Bapi Pahar, Don R. Canfield, Ross P. Tarara, Donald L. Sodora, Norbert Bischojberger, Marta Marthas

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Previous studies have demonstrated that tenofovir (9-[2-(phosphonomethoxy) propyl] adenine; PMPA) treatment is usually very effective in suppressing viremia in macaques infected with simian immunodeficiency virus (SIV). The present study focuses on a subset of infant macaques that were chronically infected with highly virulent SIVmac251, and for which prolonged tenofovir treatment failed to significantly suppress viral RNA levels in plasma despite the presence of tenofovir-susceptible virus at the onset of therapy. While untreated animals with similarly high viremia developed fatal immunodeficiency within 3-6 months, these tenofovir-treated animals had significantly improved survival (up to 3.5 years). This clinical benefit occurred even in animals for which tenofovir had little or no effect on CD4+ and CD8+ lymphocyte counts and antibody responses to SIV and test antigens. Thus, the clinical benefits of tenofovir were larger than predicted by plasma viral RNA levels and other routine laboratory parameters.

Original languageEnglish (US)
Pages (from-to)900-914
Number of pages15
JournalJournal of Acquired Immune Deficiency Syndromes
Volume36
Issue number4
DOIs
StatePublished - Aug 1 2004

Fingerprint

Tenofovir
Simian Immunodeficiency Virus
Macaca
Viremia
Viral RNA
Adenine
CD4 Lymphocyte Count
Antibody Formation
Therapeutics

Keywords

  • AIDS
  • Macaque
  • PMPA
  • Simian immunodeficiency virus
  • Survival
  • Tenofovir

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Cite this

The clinical benefits of tenofovir for simian immunodeficiency virus-infected macaques are larger than predicted by its effects on standard viral and immunologic parameters. / Van Rompay, Koen K.A.; Singh, Raman P.; Brignolo, Laurie L.; Lawson, Jonathan R.; Schmidt, Kimberli A.; Pahar, Bapi; Canfield, Don R.; Tarara, Ross P.; Sodora, Donald L.; Bischojberger, Norbert; Marthas, Marta.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 36, No. 4, 01.08.2004, p. 900-914.

Research output: Contribution to journalArticle

Van Rompay, Koen K.A. ; Singh, Raman P. ; Brignolo, Laurie L. ; Lawson, Jonathan R. ; Schmidt, Kimberli A. ; Pahar, Bapi ; Canfield, Don R. ; Tarara, Ross P. ; Sodora, Donald L. ; Bischojberger, Norbert ; Marthas, Marta. / The clinical benefits of tenofovir for simian immunodeficiency virus-infected macaques are larger than predicted by its effects on standard viral and immunologic parameters. In: Journal of Acquired Immune Deficiency Syndromes. 2004 ; Vol. 36, No. 4. pp. 900-914.
@article{e70dae2f09834d8f93d3360013c7ec0c,
title = "The clinical benefits of tenofovir for simian immunodeficiency virus-infected macaques are larger than predicted by its effects on standard viral and immunologic parameters",
abstract = "Previous studies have demonstrated that tenofovir (9-[2-(phosphonomethoxy) propyl] adenine; PMPA) treatment is usually very effective in suppressing viremia in macaques infected with simian immunodeficiency virus (SIV). The present study focuses on a subset of infant macaques that were chronically infected with highly virulent SIVmac251, and for which prolonged tenofovir treatment failed to significantly suppress viral RNA levels in plasma despite the presence of tenofovir-susceptible virus at the onset of therapy. While untreated animals with similarly high viremia developed fatal immunodeficiency within 3-6 months, these tenofovir-treated animals had significantly improved survival (up to 3.5 years). This clinical benefit occurred even in animals for which tenofovir had little or no effect on CD4+ and CD8+ lymphocyte counts and antibody responses to SIV and test antigens. Thus, the clinical benefits of tenofovir were larger than predicted by plasma viral RNA levels and other routine laboratory parameters.",
keywords = "AIDS, Macaque, PMPA, Simian immunodeficiency virus, Survival, Tenofovir",
author = "{Van Rompay}, {Koen K.A.} and Singh, {Raman P.} and Brignolo, {Laurie L.} and Lawson, {Jonathan R.} and Schmidt, {Kimberli A.} and Bapi Pahar and Canfield, {Don R.} and Tarara, {Ross P.} and Sodora, {Donald L.} and Norbert Bischojberger and Marta Marthas",
year = "2004",
month = "8",
day = "1",
doi = "10.1097/00126334-200408010-00003",
language = "English (US)",
volume = "36",
pages = "900--914",
journal = "Journal of acquired immune deficiency syndromes (1999)",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - The clinical benefits of tenofovir for simian immunodeficiency virus-infected macaques are larger than predicted by its effects on standard viral and immunologic parameters

AU - Van Rompay, Koen K.A.

AU - Singh, Raman P.

AU - Brignolo, Laurie L.

AU - Lawson, Jonathan R.

AU - Schmidt, Kimberli A.

AU - Pahar, Bapi

AU - Canfield, Don R.

AU - Tarara, Ross P.

AU - Sodora, Donald L.

AU - Bischojberger, Norbert

AU - Marthas, Marta

PY - 2004/8/1

Y1 - 2004/8/1

N2 - Previous studies have demonstrated that tenofovir (9-[2-(phosphonomethoxy) propyl] adenine; PMPA) treatment is usually very effective in suppressing viremia in macaques infected with simian immunodeficiency virus (SIV). The present study focuses on a subset of infant macaques that were chronically infected with highly virulent SIVmac251, and for which prolonged tenofovir treatment failed to significantly suppress viral RNA levels in plasma despite the presence of tenofovir-susceptible virus at the onset of therapy. While untreated animals with similarly high viremia developed fatal immunodeficiency within 3-6 months, these tenofovir-treated animals had significantly improved survival (up to 3.5 years). This clinical benefit occurred even in animals for which tenofovir had little or no effect on CD4+ and CD8+ lymphocyte counts and antibody responses to SIV and test antigens. Thus, the clinical benefits of tenofovir were larger than predicted by plasma viral RNA levels and other routine laboratory parameters.

AB - Previous studies have demonstrated that tenofovir (9-[2-(phosphonomethoxy) propyl] adenine; PMPA) treatment is usually very effective in suppressing viremia in macaques infected with simian immunodeficiency virus (SIV). The present study focuses on a subset of infant macaques that were chronically infected with highly virulent SIVmac251, and for which prolonged tenofovir treatment failed to significantly suppress viral RNA levels in plasma despite the presence of tenofovir-susceptible virus at the onset of therapy. While untreated animals with similarly high viremia developed fatal immunodeficiency within 3-6 months, these tenofovir-treated animals had significantly improved survival (up to 3.5 years). This clinical benefit occurred even in animals for which tenofovir had little or no effect on CD4+ and CD8+ lymphocyte counts and antibody responses to SIV and test antigens. Thus, the clinical benefits of tenofovir were larger than predicted by plasma viral RNA levels and other routine laboratory parameters.

KW - AIDS

KW - Macaque

KW - PMPA

KW - Simian immunodeficiency virus

KW - Survival

KW - Tenofovir

UR - http://www.scopus.com/inward/record.url?scp=3242677046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242677046&partnerID=8YFLogxK

U2 - 10.1097/00126334-200408010-00003

DO - 10.1097/00126334-200408010-00003

M3 - Article

C2 - 15220696

AN - SCOPUS:3242677046

VL - 36

SP - 900

EP - 914

JO - Journal of acquired immune deficiency syndromes (1999)

JF - Journal of acquired immune deficiency syndromes (1999)

SN - 1525-4135

IS - 4

ER -